Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated to proteinaceous toxin or fragment thereof
Patent
1997-08-12
2000-03-28
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated to proteinaceous toxin or fragment thereof
4241341, 4241381, 4241431, 4241561, 53038885, 5303897, 5303917, 5303877, A61K 39395, A61K 3944, C07K 1630, C07K 14415
Patent
active
060428295
ABSTRACT:
Cytotoxic biotherapeutic agents effective for treating certain types of cancer in humans are provided which comprise the TP-3 murine monoclonal antibody chemically conjugated to pokeweed antiviral protein (PAP). The invention further provides a method which utilizes the disclosed cytotoxic biotherapeutic agents to systemically treat cancer patients. With slight modifications the method of the present invention should be generally applicable to preparation and use of other cytotoxic biotherapeutic agents using chemical or recombinant derivatives of the TP-3 or TP-1 antibodies or PAP toxin. The invention is applicable to cancer patients who express the p80 antigen recognized by the TP-1/TP-3 antibodies either on the surface of their tumor cells or on the tumor blood vessels.
REFERENCES:
patent: 4340535 (1982-07-01), Voisin et al.
patent: 4350626 (1982-09-01), Masuho et al.
patent: 4357273 (1982-11-01), Masuho et al.
patent: 4359457 (1982-11-01), Neville, Jr. et al.
patent: 4363758 (1982-12-01), Masuho et al.
patent: 4368149 (1983-01-01), Masuho et al.
patent: 4379145 (1983-04-01), Masuho et al.
patent: 4414148 (1983-11-01), Jansen et al.
patent: 4450157 (1984-05-01), Masuho et al.
patent: 4590071 (1986-05-01), Scannon et al.
patent: 4792447 (1988-12-01), Uhr et al.
patent: 4806494 (1989-02-01), Pastan et al.
patent: 4831117 (1989-05-01), Uckun
patent: 4888415 (1989-12-01), Lambert et al.
patent: 4906469 (1990-03-01), Jansen et al.
patent: 4916213 (1990-04-01), Scannon et al.
patent: 4956453 (1990-09-01), Bjorn et al.
patent: 4958009 (1990-09-01), Bjorn et al.
patent: 5167956 (1992-12-01), Neville, Jr. et al.
(1994) New York, American Cancer Society, pp. 1-28, Publication 94-375M--No. 5008.94 "American Cancer Society: Cancer Facts and Figures--1994".
Anderson, P.M. et al., (1995) Anticancer Research, 15(5A):1794-1795 "TP-3 Antibody--Pokeweed Antiviral Protein (TP-3-PAP) Conjugate Efficiently Kills Osteosarcoma".
Anderson, P.M. et al., (1995) Cancer Research, 55(6):1321-1327 "In Vitro and in Vivo Cytotoxicity of an Anti--Osteosarcoma Immunotoxin Containing Pokeweed Antiviral Protein".
Balis et al., (1993) Principles and Practice of Pediatric Oncology, 2nd ed., Pizzo et al., eds., J.B. Lippincott Company, Philadelphia, pp. 197-245 "General Principals of Chemotherapy".
Balis, F.M. et al., Principles of Multimodal Therapy, Chapter 10, pp. 197-245 "General Principles of Chemotheraphy".
Bologhesi et al., (1992) Clin. Exp. Immunol., 89:341 "A comparison of anti-lymphocyte immunotoxins containing different ribosome--inactivating proteins and antibodies".
Bruland et al., (1993) Frontiers of Osteosarcoma Research, Novak et al., eds., Hogrefe and Huber Publishers, pp. 149-159 "Immunoscintigraphy and radioimmunotherapy: Useful approaches in the management of osteogenic sarcoma".
Bruland et al., (1986) Int. J. Cancer, 38:27 "New monoclonal antibodies specific for human sarcomas".
Bruland et al., (1986) Br. J. Cancer, 56(1):21-25 "Selective Localization of Radiolabeled Anti-Sarcoma Antibody".
Bruland et al., (1988) Cancer Research, 48:5302 "Expression and charateristics of a novel human osteosarcoma--associated cell surface antigen".
Byers, V.S. et al., (Oct. 1987) Cancer Research, 47:5042-5046.
Cheung et al., (1985) J. Nat. Cancer Instit., 77:739.
Chin et al., (1986) Hybridoma, 5:339.
Dore et al., (1993) Nucl. Acids Res., 21:4200-4205.
Elias et al., (1989) Seminars in Oncology, 16:305-311 "Adjuvant chemotherapy for soft tissue sarcoma: an approach in search of an effective regimen".
Embelton et al., (1981) Br. J. Cancer, 43:582.
Embleton et al., (Nov. 1986) Cancer Res., 46:5524-5528.
Erice et al., Blood.
Fodstad et al., (1986) Int. J. Cancer, 38:33 "Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma".
Folkman et al., (1991) Biological Therapy of Cancer: Alternative Strategies for Biologic Therapy, DeVita et al., eds., J.B. Lippincott Company, Chapter 30, pp. 743-753 "Antiangiogensis".
Frei et al., (1993) Frontiers of Osteosarcoma Research, Novak et al., eds., Hogrefe and Huber, pp. 5-13 "Osteogenic Sarcoma: The Development of Curative Treatment".
Gellego, J. et al., (1985) Database Embase, 21(11):511-521.
Ghetti et al., (Aug. 1994), Blood, 84:702-707.
Gottstein et al., (1994) Annals of Oncology, 5:S97.
Guther et al., (Feb. 1993), Leukemia, 7:298-309.
Haines, D.M. et al., (1989) Anticancer Research, 9:903-908.
Hertler et al., (1989) J. Clin Oncol., 7:1932.
Hosi et al., (1982) Cancer Research, 42:654.
Houston et al., (1987) Immunological Antibody Conjugates in Radioimaging and Therapy of Cancer, C.W. Vogel, ed., New York, Oxford University Press, p. 71 "Immunotoxins made with Toxins and Hemitoxins other than Ricin".
Irvin et al., (1992) Pharmac. Ther., 55:279 "Pokeweed antiviral protein: ribosome inactivation and therapeutic applications".
Irvin, (1983) Pharmacol. Ther., 21:371.
Jansen et al., (1992) Leukemia, 7:290.
Kersey et al., (Jun. 19-21, 1992), Third International Symposium on Immunotoxins, Orlando, FL, p. 95.
McClay E. F., (1989) Seminars in Oncology, 16:264-272 "Epidemiology of Bone and Soft Tissue Sarcomas".
McClay et al., (1989) Seminars in Oncology, 16:328-332 "Immunotherapeutic Approaches to the Treatment of Bone and Soft Tissue Sarcomas".
Mendelsohn, (1992) J. Natl Cancer Inst., 13:125-131.
Meyers et al., (1993) J. of Clinical Oncology, 11:4490453 "Osteogenic sarcoma with clinically detectable metastasis at initial presentation".
Milstein, (1980) Sci. Am., 243:66.
Myers et al., (1988) Transplantation, 46:240.
Myers et al., (1991) J. Immun. Methods, 136:221-238.
Myers et al., (1995) PNAS USA, 92:9575-9579.
Canevari et al., (1994) Annals. of Oncology, 5:698-701.
Naramura, (1993) Cancer Immunol. Immunother., 37:343-349.
Pastan et al., (1986) Cell, 47:641 "Immunotoxins".
Perentesis et al., (1988) PNAS USA, 85:8386.
Perentesis et al., (1991/1992) Biofactors, 3:178-184.
Perentesis et al., (Mar. 1, 1993) Abstract CA-53586.
Perentesis et al., (Sep. 1, 1987) Abstract AI-00793.
Ramakrishnan, S. et al., (Apr. 1984) Cancer Research, 44(4):1398-1404.
Ramsay et al., (Jun. 1992) 3rd Int'l. Symposium on Immunotoxins, ORlando, FL.
Raymond et al., (1987) Seminars in Diagnostic Pathology, 4:212-236 "Osteosarcoma chemotherapy effect: A prognostic factor".
Rivera et al., (Oct. 28, 1993) The New England J. of Med., 329:1289-1295.
Roth, J.A. et al., (1978), Database Embase, Elsevier Science Publishers, Abstract & Cancer, 41(3):814-819.
Thomas, (1992) Drugs of Today, 28:311-331.
Tsai et al., (1990) Cancer Research, 50:152.
Tsang et al., (1986) J. Nat. Cancer Inst., 77:1175.
Uckun et al., (1985), J. Immunol, 134:2010.
Uckun et al., (1986) J. Exp. Med., 163:347 "Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic lsukemia".
Uckun et al., (1988) Blood, 7(13).
Uckun et al., (1989) In: Human Tumor Antigens and Specific Tumor Therapy, R. Metzger & M. Mitchell, eds,. Alan R. Liss, Inc., NY, NY, pp. 231-241.
Uckun et al., (1989) Int. J. Radiat. Biol., 56:611-615.
Uckun et al., (1990) Blood, 76:2449.
Uckun et al., (Feb. 1993) Leukemia, 7:341.
Uckun et al., (Jun. 19-21, 1992), Third International Symposium on Immunotoxins, Orland, FL, p.131.
Uckun et al., (May 1, 1992) Blood, 79:2201.
Uckun et al., (May 1992), Blood, 79:2649-2661.
Uckun et al., In: Membrane--Mediatal Cytotoxicity, pp. 243-256.
Uckun, (1988) Antibody Immunoconjugates and Radiopharmaceutics, 1:247.
Uckun, (Nov. 9, 1993) Brit. J. Haematol., 85:435.
Vitetta et al., (1991) Biologic Therapy of Cancer, DeVita et al., eds., J.B. Lippincott Company, pp. 482-495 "Immunotoxins".
Vitetta et al., (2987) Science, 225:1098-1104.
Wada et al., (1988) Cancer Research, 48:2273.
Ward et al., (1994) Journal of Clinical Oncology, 12:1849-1858 "Pulmonary Metastases of Stage IIB Extremity Osteosarcoma and Subsequent Pulmonary Metastases".
Wingo et al., (Jan./Feb. 1995) A Cancer J. for Clinicians, 45:8-30.
Winke
Anderson Peter M.
Uckun Fatih M.
Bansal Geetha P.
Hutzell Paula K.
Regeants of the University of Minnesota
LandOfFree
Biotherapy of cancer by targeting TP-3/P80 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biotherapy of cancer by targeting TP-3/P80, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biotherapy of cancer by targeting TP-3/P80 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1323678